Kyverna Therapeutics Stock Performance
- Trading session (Wednesday, 21 Nov 2026): Shares increased 3.6 % to a closing price of USD 5.92.
- Market capitalization: USD 360.6 million.
- Shares outstanding: 61.8 million.
- Volume: USD 4.6 million worth of shares traded in the last 24 hours.
- Price trend: Since the previous month‑end, the stock has declined 15.17 %.
- Moving average: 200‑day simple moving average is USD 8.20.
- 52‑week range: High of USD 13.67 (15 Dec 2025); low of USD 5.61 (14 Oct 2026).
Recent Clinical Development
Kyverna Therapeutics reported that the one‑year follow‑up of its Phase 2 registry trial of miv‑cel in patients with stiff person syndrome shows sustained improvements across all primary and secondary endpoints. Patients maintained clinically meaningful gains in walking speed, disability, stiffness, and sensory symptoms, with most remaining free of chronic immunosuppressive therapy.
Safety data remained consistent with earlier observations: no severe cytokine release syndrome or neurotoxicity occurred; only manageable neutropenia and isolated serious adverse events were reported. These results support the company’s claim that a single dose of miv‑cel can provide durable, drug‑free remission in this rare autoimmune condition.
In a simultaneous SEC filing, AIGH Capital Management and associated entities disclosed holding approximately 5.9 % of Kyverna’s common stock, indicating ongoing institutional interest.
Comparative Stock Activity (Last 24 Hours)
| Ticker | Change | Current Price | Market Cap (mn USD) | P/E Ratio |
|---|---|---|---|---|
| SGU (Star) | -0.31 % | USD 12.96 | 429.8 | 5.88 |
| DMAC (Diamedica Therapeutics) | +10.17 % | USD 8.77 | 424.4 | – |
| MNRO (Monro) | +3.91 % | USD 14.29 | 431.4 | 60.81 |
| CBK (Commercial Bancgroup) | +0.13 % | USD 31.27 | 429.3 | – |
| VRRM (Verra Mobility) | +7.12 % | USD 2.93 | 427.1 | 9.71 |
Company Overview
Kyverna Therapeutics Inc. is a U.S.‑based biotechnology company focused on oncology and immunology. The company’s initial public offering was scheduled for February 8 2024 on the Nasdaq stock exchange.
